Unraveling Organ-Specific Response Heterogeneity and Mixed Response Patterns in Advanced non-small cell lung cancer (NSCLC): A Cross-Comparison of Real-World Evidence and Phase III Clinical Trial Data

Lung cancer is the most common cancer worldwide and affects millions of people each year. One common form is non-small cell lung cancer (NSCLC), which often spreads to other parts of the body such as the liver, bones, and brain when it becomes advanced. Once the cancer has spread, it is usually treated with medicines that work throughout the whole body, known as systemic treatments.

In everyday medical practice, doctors often see that these treatments do not work equally well in all parts of the body within the same person. For example, a lung tumor may shrink, while a tumor in the liver continues to grow. This uneven pattern of treatment effect is called a mixed response (also known as a discordant response), meaning that different tumors in the same patient respond differently to the same drug.

We will study this problem using high-quality data from several large clinical trials in people with advanced non-small cell lung cancer. These trials include patients treated with three major types of systemic therapies: immune checkpoint inhibitors (drugs that help the immune system recognize and attack cancer cells), tyrosine kinase inhibitors (targeted drugs that block signals cancer cells need to grow), and chemotherapy (drugs that kill fast-growing cancer cells). To ensure that our findings are applicable to real-world patients, we will also compare these clinical trial results with real-world data collected from routine clinical practice.

Our main goal will be to understand whether the liver plays a special role in this mixed response. Some doctors believe that the liver may act as a “safe haven” for cancer cells, where treatments are less effective even when they work well in other organs. We will compare how tumors in different organs respond to treatment, focusing on whether liver tumors are more likely to resist therapy than tumors elsewhere in the body.

We will carry out this research by carefully analyzing existing clinical trial data, looking at tumor changes in different organs over time. We will compare responses across treatment types to see whether liver-related resistance happens with all therapies or mainly with certain drugs. This approach allows us to answer important questions without exposing patients to any additional procedures or risks.

This research is necessary because understanding why treatments fail in specific organs could lead to better care for patients. If the liver is shown to be a common site of treatment resistance, doctors may be able to improve outcomes by combining whole-body treatments with local treatments, such as targeted radiation or surgery, for liver tumors. Ultimately, our findings could help doctors choose more effective treatment strategies and improve survival and quality of life for people with advanced lung cancer.